This content is machine translated RAINBOW Study New standard in the second line? Drugs that are well established in first-line advanced gastric cancer continue to achieve relatively poor survival prognoses in second-line settings. A new study (RAINBOW) now demonstrates the efficacy of ramucirumab…
